Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12534MR)

This product GTTS-WQ12534MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12534MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ398MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ1304MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ6024MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ5152MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ14911MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ12588MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ5236MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3650MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1187982
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW